CTLA4 and cancer: Checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, have shown remarkable success in treating various cancers [3,4].